Takeda maps out a discovery alliance aimed at breaking through the safety and efficacy boundaries that limit the first-gen gene therapies
MIT headliner Harvey Lodish and Jiahai Shi in Hong Kong leant some of their work in red blood cells to help found Rubius, a Flagship startup that has been disappointing investors with its inability to stay on track with the clinical work.
But Lodish and Shi also backed another, lesser-known startup — Carmine Therapeutics — that has now inked its first Big Pharma partnership. And this one is hoping to make it big in one of the hottest fields in drug R&D: gene therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.